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Five antibodies directed against digoxin were grown and
characterized. Two separation techniques were tested
to find the better method of separating bound and free
fractions of ligand after competitive reactions with
the antibodies. Charcoal separation was chosen. The
antibodies were analyzed for affinity constant by the
Scatchard Analysis. Cross reactivity data for two of
the antibodies were collected. Four of the antibodies
have satisfactory affinity constants for use in a
digoxin assay. Cross reactivity studies showed varying
amounts of cross reactivity with digoxin metabolites,
but none with the steroids and lipid tested.
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INTRODUCTION
The research project that is presented here involves
the characterization of monoclonal antibodies directed
against digoxin. Several types of activities were
involved in this research. The first stage involved
growing the antibodies in vitro. Next were the sets of
experiments to separate digoxin bound to antibody and
that which was not. The Scatchard experiments and
analysis, which determine the affinity constant follow,
and the crossreactivity studies complete the project.
Before getting into the descriptions of the
experiments, a brief overview of both digoxin and
monoclonal antibodies is given.
Digoxin is a cardiac glycoside derived from digitalis.
Cardiac glycosides are composed of an aglycone (a
steroid nucleus and a lactone ring) linked to a portion
with one to four sugar molecules. The sugars modify
water solubility and potency while the steroid portion
controls pharmacologic activity. These drugs are
derived from the foxglove plant, Digitalis purpura.
Foxglove had been known to have medicinal properties
even before Withering described them in 1785.




ATPase. This enzyme, sometimes called the 'sodium
pump,
'
drives the transport of sodium ions out of the
cell while transporting potassium inwards. This
exchange occurs in the ratio of three sodium ions to
two potassium ions in order to maintain the
characteristic intracellular ionic environment and
generate an electrochemical gradient across the cell
2
membrane. When ATPase is inhibited, the concentration
of intracellular sodium ions is increased, also
accompanied by an increased concentration of calcium
3
ions .
This increased level of calcium increases the force and
velocity of myocardial systolic contraction by causing
the filaments of myosin and actin to interact. The
cardiac glycosides also slow conduction through the AV
node, controlling the ventricular rate in atrial
fibrillation. The digitalis derivatives are used to
produce long-term increases in cardiac contractability
and in treatment of rhythm disturbances. At
therapeutic levels, the pharmacological effects of
digoxin and other cardiac glycosides are directed at
the heart, although ATPase is found on the surface of
all cells.
Digoxin blood levels must be kept in a narrow range
(approximately 0.8-2.0 ng/ml) owing to a low
toxic: therapeutic ratio. There is a poor correlation
between dosage and plasma concentration caused by many
factors, including differences in bioavailability of a
preparation from patient to patient, drug interactions
(such as with quinidine) , renal impairment, extremes of
age, thyroid disease, and hypokalemia. The need for
accurate digoxin assays is further evidenced by the
fact that symptoms of digoxin toxicity are sometimes
difficult to distinguish from those of the disease
6
being treated. Contrary to past thought, it has
recently been acknowledged that digoxin is metabolized
in vivo. The metabolism can be extensive and varies
fi 7
according to the individual patient.
'
Because of the need to measure blood levels of digoxin,
there have been many analytical procedures developed
including liquid chromatographic and gas
chromatographic-mass spectrophometric methods.
However, during the last 15 years, digoxin blood levels
have been measured almost exclusively in the routine
clinical chemistry laboratory by immunoassay
procedures. These include radioimmunoassay,
fluorescence polarization immunoassay and enzyme
6
immunoassay.
Common to all of these immunoassays is the use of
antibodies to digoxin. Polyclonal antibodies, a
mixture of various antibodies from animal serum
directed against digoxin, have been used extensively.
Today monoclonal antibodies are gaining in availability
but have not replaced polyclonals. Monoclonal
antibodies have many advantages over polyclonal
antisera. These include: an indefinite supply of
antibody with constant characteristics, availability of
antibody for different and discrete epitopes, rapid
equilibration in binding of antigen, easy purification,
8
and low non-specific binding. The rapid equilibration
of monoclonal antibodies versus polyclonals may be
explained by a somewhat complicated phenomenon.
Monoclonal reactions are bimolecular under most
conditions. Conversely, high affinity binding in
polyclonal antisera is sometimes achieved by
synergistic antibody combinations which may take a long
time to equilibrate. Also, monospecific antibody can
be obtained from impure immunogen, and affinity and
fine specificity may be selected to suit the
application. Possible disadvantages are that low
affinities predominate and that there is a dependence
on a single epitope, which might not be representative
of the antigen as a whole.
Monoclonal antisera can be used for applications that
utilize their specificity for epitopes. An example of
this is their ability to immunoextract enzymes from
solution without inhibiting enzymatic sites. The
ability to select appropriate epitopic sites allows for
sandwich techniques for immunoradiometric (IRMA) ,
precipitation or fluorometric assays. IRMA requires
particularly clean antibody populations for which
monoclonal antisera are ideal. A lifesaving technique
using Fab fragments or entire antibodies has been used
to remove digoxin from plasma in toxicity
cases.6'9
Monoclonal antibodies are produced by a multistep
procedure. Mice or rats are injected intraperitoneally
with immunogen. The material is conjugated with a
carrier protein foreign to the host animal to induce an
immune response. In the case of the monoclonals to be
investigated, human serum albumin serves as the carrier
protein. The animals are injected periodically over a
90-120 day period. Repeated introduction of antigenic
material raises the affinity constants of the desired
antibodies. Several days after the last booster, the
animals are sacrificed.
Spleens are removed aseptically and a suspension of
nucleated cells is prepared. Fusion of these
splenocytes to murine melanoma cells is commonly
achieved with the use of polyethylene glycol (PEG) .
The murine melanoma cells used are grown from a cell
line that is deficient in hypoxanthine guanine
phosphoribosyl transferase (HGPRT) . When grown in a
medium containing hypoxanthine, aminopterin and
thymidine (HAT medium) , melanoma cells cannot
synthesize nucleotides. The nucleotide synthesis
pathway is blocked by the presence of aminopterin. The
salvage pathway is partially blocked by the absence of
HGPRT. HAT medium will allow only fused cells to grow
since non-fused splenocytes have a limited in-vitro
life span.
These fused splenocyte-melanoma hybrid cell lines are
allowed to grow. After several
days'
incubation,
supernatants are analyzed for the presence of
antibodies. If antibodies to digoxin are detected, the
cell lines producing those antibodies are isolated.
The isolated cell lines are allowed to continue growing
and producing antibody. Supernatant, containing
antibody, is collected and purified. Further antibody
analysis is now possible.
EXPERIMENTAL
Antibody production:
Cells which were known to be producing anti-digoxin
antibodies were frozen in liguid nitrogen. The cells
were from rat or mouse sources. They were thawed and
placed in growth medium. At this stage, allowing the
cells to reproduce was the goal. Once the cultures had
actively growing cells, they were diluted and poured
onto agarose plates. From these plates, individual
colonies were transferred to other plates with growth
wells in them. After a couple of days, the supernatant
fluid was tested for anti-digoxin activity.
The ELISA methodology was used in this step.
Ninety-six well plates were coated with digoxin which
had been conjugated to a protein. The protein will
adhere to the plastic walls and bottoms of the wells.
The plates were washed and supernatant from the
cultures were added. After an incubation period, the
plates were washed again to remove anything that was
not bound. A solution containing antibodies (linked to
an enzyme) directed against rat or mouse antibodies was
pipetted into the appropriate wells. Another
incubation followed. During the second incubation, if
anti-digoxin antibodies were present, the following
sandwich containing the enzyme-labeled antibody formed:
Digoxin-Antibody/Anti-Rat (or Mouse) Antibody/Enzyme
The addition of the substrate for the enzyme produced
color which could be quantified.
Cell lines that were producing antibodies were
transferred to larger vessels. The supernatant medium
which contained antibodies was removed and frozen.
More nutrient medium was added to replace that which
had been removed. This was done on a two-day cycle
until sufficient quantities of antibody had been
harvested.
Five antibodies were grown and collected in this
manner. Three rat antibodies, AB 1, AB 2, and AB 3
were obtained as were two mouse antibodies, AB 4 and AB
5. The characterization of these antibodies comprised
the bulk of my research.
Competitive Binding Assays:
The experiments which follow were set up as competitive
binding assays. In these types of tests labeled
antigen, or ligand, is mixed with the actual ligand.
8
Both forms compete for the available binding sites on
the antibody. If the concentration of the unlabeled
analyte far exceeds that of the labeled form, very few
antibody sites will hold labeled antigen. Therefore,
if one counts the bound fraction and finds low levels
of labeled analyte, it can be inferred that there is a
high concentration of unlabeled substance in the
sample. High levels of labeled ligand found when
counting the free fraction demonstrate the same
relationship.
When setting up a competitive assay, one makes the
14
following assumptions:
1. The analyte is a homogeneous species.
2. The antibody is a homogeneous species.
3. One molecule of antibody binds one molecule of
ligand.
4. The analyte and antibody reaction is governed by
first-order mass action (a bimolecular reaction) .
Thus, no cooperative effects are considered.
5. Labeled and unlabeled ligand have identical
physical-chemical properties (except for the
presence of the label) and participate in the
reaction identically-
6. The reaction proceeds to equilibrium.
7. Ligand bound to antibody can be separated from free
ligand perfectly without disturbing the
equilibrium.
8. The ratio of bound analyte to unbound analyte can
be measured perfectly.
Separation Techniques:
The last step of an antigen - antibody incubation
experiment requires the separation of free and
bound fractions. Either fraction may be analyzed
to determine the quantity of labeled analyte which
was bound.
Ideal separation has several requirements. The
first is complete separation of the bound and free
fractions with no interference with the binding
reaction. Also, simple techniques which are quick
and inexpensive are needed, as well as readily
available reagents.
Two types of separations have been analyzed. The
first uses polyethylene glycol in which bound
fractions are precipitated. The other technique
uses activated charcoal to precipitate small,
unbound particles. The experiments yielded
information about the completeness of the




Polyethylene glycol (PEG) precipitates antibody whether
it is bound to ligand or not. This is a type of
fractional precipitation. Researchers have found that
dissociation of bound ligand does not occur upon the
addition of PEG. The precipitation is dependent on
electrostatic forces. It has been noted that the
separation is dependent on concentration of PEG,
protein concentration, pH and ionic composition of the
reaction solution.
Only one experiment with one variable was performed.
It was hoped that the optimum concentration of PEG for
separation could be found. The incubation reaction was
run at conditions known to be favorable for the binding
of antigen to antibody and at which most of the digoxin
was bound.
Materials and Methods:
Polyethylene glycol 6000 (Kodak) was dissolved in
phosphate buffered saline (PBS) (10.5 mM phosphate, pH
7.4) with 0.25% bovine serum albumin (BSA) (Sigma) with
the aid of a microwave oven. A concentration series of
60, 40, 30, 20, 10 and 0% was prepared. The solutions
were then cooled to 4C. Meanwhile, a rabbit serum
11
pool containing polyclonal antibodies against digoxin
was diluted 1:10 with 0.025% BSA in PBS. Tritiated
digoxin (New England Nuclear) was diluted to a
concentration of 1.5 E-8 M in the BSA-PBS solution.
Cold'
digoxin was prepared by diluting a stock
solution of digoxin in pyridine (Kodak) to 1 E-5 M in
the BSA-PBS solution.
Three sets (in duplicate) of polypropylene tubes
(Sarstedt) were prepared as shown on Table 1.
These tubes were incubated at room temperature on a
shaker. After a one-hour incubation, 0.25 ml of
the chilled PEG was added to the appropriate tubes
and vortexed briefly. The tubes were centrifuged
at 15,500 x g for 10 minutes. Five hundred
microliter aliquots of the supernatant were removed
and placed in scintillation vials (Kimble) . Four
milliliters of Dow HP/b scintillation fluid was
added to each tube and vortexed. All scintillation
tubes were counted on the LKB Rackbeta.
Discussion:
Graphs of the results appear in Figure 1. Maximum
separation occurs at the highest concentration of PEG.
Even at this concentration, complete separation is not





Hot Digoxin Cold Digoxin Antibody PBS/0.25% BSA
0.05 ml - - 0.700 ml
0.05 ml 0.05 ml
- 0.650 ml
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demonstrate, a large excess of digoxin does not
interfere with the test in any way.
Conclusion:
This method, at the conditions used, does not appear to
offer the necessary extent of separation of the bound
and free fractions. Further experiments with different
conditions might provide better results. However, the
next method of separation was so successful that
further testing with PEG was not attempted.
Separation by Activated Charcoal:
Charcoal is a substance which is widely used to
separate bound and free fractions in competitive
immunoassays. It does this by adsorption of the small
molecules, such as unbound drug or hormone in an assay.
The technique utilizes charge - charge interactions so
concentrations of electrolytes and proteins can affect
the separation.
12
It has been suggested that charcoal coated with
dextran works as a molecular sieve, allowing adsorption
12
of only small molecules.
Binoux and Odell studied
the effects of dextran on charcoal and found that at
15
low protein concentrations, dextran slightly improved
the quality of separation. They discovered that
"dextran decreases, but does not eliminate, the
adsorption of a certain amount of
bound"
fraction.
They also studied the incubation time required to
accomplish the separation. Maximum adsorption was
found at 15 minutes and remained constant through 60
minutes. These results are consistent with a similar
study done at Eastman Kodak Company -
12
Binoux and Odell found protein concentrations to have
a great effect on adsorption. They recommended
performing the assay at different protein levels to
determine optimum conditions. The incorporation of
protein has been found to allow untreated charcoal to
be used in the types of experiments. Non-coated
charcoal has been found to strip bound antigen,
particularly when low affinity antibodies are used.
This experiment was performed to find satisfactory
levels of charcoal and protein for separation and to
determine if dextran coating is beneficial.
16
Materials and Methods:
Three grams of Norit A (Eastman Chemical) and 0.15 g
Dextran T70 (Pharmacia) were each suspended in 80 ml
phosphate buffered saline (PBS), pH 7.4. These
mixtures were combined and stirred for 18 hours at
10
C. Likewise, 3 grams of Norit A were suspended in 80
ml of PBS and an additional 80 ml of PBS were added.
This suspension was stirred as above.
The suspensions were washed by centrifugation at
11,000 x g for 15 minutes and resuspended in PBS
for a total of three washes. This step eliminated
unbound dextran and fines. Final resuspension was
to a total volume of 80 ml.
A rabbit serum pool with anti-digoxin antibody was
diluted 1:10 in 0.25% BSA dissolved in PBS. Tritiated
digoxin (New England Nuclear) was diluted to 1 E-8
molar in PBS with 0.25% BSA. Unlabeled digoxin was
dissolved in pyridine (Eastman Chemical) to a
concentration of 1 E-3 molar. It was further diluted
to 1 E-5 molar in PBS with 0.25% BSA. Six conditions





Hot Digoxin Cold Digoxin Antibody 1% BSA 0.25% BSA
0.05 ml - - 0.70 ml
0.0 5 ml - - - 0. 70 ml
0.05 ml 0.05 ml - 0.65 ml
0.05 ml 0.05 ml - - 0.65 ml
0.05 ml - 0.05 ml 0.65 ml
0.05 ml - 0.05 ml
- 0.65 ml
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Both types of charcoal were diluted in 0.25% BSA in
PBS to obtain initial percentages of 3.75, 1.88,
0.94, 0.23, 0.06, 0.03, and 0.008. Duplicate
tubes, containing digoxin, with and without
antibody were incubated, with shaking, at ambient
temperature for one hour. The series of charcoal
suspensions were added to their respective tubes.
After a minimum incubation of 15 minutes, each tube
was spun at 16,000 x g for 2 minutes. Five hundred
microliters of supernatant were removed from each
tube and placed in scintillation tubes. Dow
scintillation fluid (4.0 ml) was added to the
tubes. Each tube was briefly vortexed and read on
the LKB Rackbeta, model 1214, scintillation
counter.
Discussion :
Graphs of the results appear in Figures 2 &3. Total
counts were approximately 17,600 per minute for tubes
with only 50 ul
'hot'
digoxin and 950 ul 0.25% BSA in
PBS. At the lowest levels of charcoal, essentially all
of the labeled digoxin is recovered in the supernatant.
Also noted is the nearly complete adsorption of unbound
digoxin by the charcoal at concentrations greater than
or equal to 0.23% This is found regardless of the
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Each point on the graphs above represents
the average of two replicates. These graphs,
at 0.25% BSA, demonstrate good separation of
the bound and free fractions of the reaction
mixture. The dextran-coated charcoal appears
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Each point on the graphs above represents
the average of two replicates. These graphs,
of 1.0% BSA, show that the charcoal removes
the free fraction from teh reaction mixture.
However, a large portion of the bound fraction
is also precipitated.
21
that the charcoal has the ability to absorb large
amounts of small molecules.
The plots of the bound fractions show interesting
results. At levels of 1% BSA, % bound for the antibody
plus digoxin tubes do not approach the 100% bound
level. This seems to indicate that the protein itself
is causing the capture and precipitation of some of the
bound fraction. Both dextran and non-dextran coated
charcoals show good separation between bound and
unbound phases. There appears to be a slight fall in
recovery of bound fraction at the higher concentration
of uncoated charcoal. This might be caused by the
stripping of the bound digoxin from the antibody.
Conclusion:
This experiment demonstrates that separation of free
and bound fractions by charcoal is feasible.
Dextran-coated charcoal will be used in the separation
phase of the following experiments. There are two
reasons for this decision. The first is to avoid any
possible stripping of ligand from antibody. The second
is based upon the observation that uncoated charcoal
seemed to settle out of suspension more quickly.
Precision in delivery of charcoal is therefore improved
22
with the usage of dextran-coated charcoal. The
concentration to be used will be 0.94% to be certain of
maximum adsorption of unbound digoxin.
Because of the success and simplicity of this method,
the third method of separation which was to be
attempted, that of an antibody bound to Staphylococcus
particles, will not be done.
Scatchard Analysis:
A characteristic of an antibody which is very important
to researchers is its affinity to the ligand against
which it is directed. In a solution, molecules are
perpetually colliding with one another. However, when
an antibody meets with its antigen, (in the proper
orientation) they become instantly bound together. The
forces which hold them together are H-H bonds, ionic
bonds, van der Waals bonds and hydrophobic
interactions. The strength of the bond depends upon
how well the antigenic determinants match the antibody
and how strong the forces
are that develop between the
molecules.
23
This binding is not irreversible. The equation that
describes the relationship is:
[L] + [Abj-^tAgAb]
where L = ligand, Ab = antibody, and AbL = the
antibody-ligand complex. According to the law of mass
action, the association rate is proportional to the
concentration of antigen and antibody. The association
rate is the rate at which the bound complex forms. It
can be expressed as kl [L] [Ab] . The dissociation rate
is the rate at which the complex breaks apart. It can
be expressed as k2 [AgAb] . At equilibrium: kl [Ab][L] =
k2 [AbL] . The kl/k2 quotient is called K, the
equilibrium (or affinity) constant. Another way to
express this is:
K= [AbL] / [Ab] [ L] .
At this point, [L] and [Ab] are the concentrations of
the unbound species.
During a competitive equilibrium experiment, a constant
quantity of antibody is used, along with a constant
concentration of labeled antigen. Unlabeled ligand
concentration is varied, but the total concentration is
always known. With these quantities in mind, a binding
curve may be drawn after an
experiment is completed.
(See figure
4 ) . The binding curve shows [AbL] as a
function of the free [L] . A curve is difficult to

























































































The transformation may be followed by the following
equations:
K= [AbL]/[Ab] [L]
[Abt]= [Abf] + [At^]
[Abt-]= Concentration of total antibody
[Abf]= Concentration of free antibody
[AbjD]= Concentration of bound antibody
K([Abt]
- [Ab^lL] = [AbL]
K[Abt][L] = [AbL](l + K [L])
[AbL] = K[L]








r/c = K - rK
(c = free fraction)
26
By plotting Bound / Free [AbL]/lL], against free [L ],
a straight line with a slope of -K, the affinity
constant, is found. This is true only if the antibody
population is homogeneous; however, with a monoclonal
antibody, this is understood to be the case. The
intercept gives us the amount of binding sites present.
The affinity constant will, in part, determine the
sensitivity of the antibody in an assay. Since digoxin
is found in body fluids in nanomolar concentrations,
high affinity antibodies are required for the necessary
sensitivity. Polyclonal antibodies have been used
extensively in the past. Pros and cons of these types
of antisera have already been discussed in another
section. A major advantage of using a monoclonal
antibody in an assay is for increased specificity.
Specificity of these monoclonal antibodies will be
discussed in detail in the section on crossreactivity .
Materials and Methods:
Digoxin (Sigma) , tritiated digoxin (New England
Nuclear) , PBS with BSA, pyridine (Kodak) and
dextran-coated charcoal were used to perform these
experiments. Microtubes (Sarstedt) , Dow Ready-Solv
HP/b scintillation fluid, scintillation vials (Kimble)
and the LKB Rackbeta scintillation counter were also
27
utilized. A quick prescreen test of the antibodies was
done to find the approximately correct dilution of
culture supernatant to use in the assay. Fifty
microliters of one of three dilutions was placed into a
microtube. The dilutions used were 1:1, 1:100, and
1:1000 antibody into PBS with 0.025% BSA. Digoxin,
being rather insoluble in many solvents, was dissolved
in pyridine. Further dilutions were made in PBS with
BSA in such a manner that the pyridine was present at a
concentration of 1% in the 100 nanomolar tube as well
as in the
'0'
tube. Six hundred microliters of PBS
with BSA were added to each tube. A 50 ul aliquot of
'hot'
digoxin was added to each tube at a concentration
of 7.5 nanomolar. For each dilution of antibody, 50 ul
of two concentrations of unlabeled digoxin were used, 0
and 100 nanomolar. An incubation for the competitive
reaction was allowed to take place at room temperature
for one hour. Separation was by the dextran-coated
charcoal procedure discussed earlier. Those dilutions
showing the highest difference in counts between 0 and
100 nanomolar unlabeled digoxin were chosen to start
the testing.
Series of tubes (in duplicate) were set up for each
antibody to be tested.
Each tube was set up in the
basic manner already described. A series
of
concentrations of
'cold' digoxin was set up to be used
23
in addition to the 0 and 100 nanomolar tubes in the
screening experiment. Concentrations of pyridine were
0.5 to 4% of the volume of digoxin in PBS. The actual
concentrations needed varied from antibody to antibody.
The concentration of labeled digoxin also had to be
varied to find the optimum for each antibody- Since
concentrations and affinities of the antibodies were in
some cases quite different, finding the best
combinations of the three parameters occasionally
required several sets of experiments. Incubations and
separations were conducted as already described.
Results :
The samples were counted and the numbers were fed into
a computer program that converted raw data into the
numbers which were desired: the bound/free ratio and
the free antigen concentration. These numbers were
then plotted by the same program. Those plots are
shown on Figures 5 & 6. The affinity constant for
each
is found on Table 3 .
Discussion:
The affinity constants
for four of the antibodies were
close in value and were in the
109 M_1
range. All of
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This figure and the one on the next page are the
Scatchard plots for the mouse and rat antibodies.
Each point on the plots represents the average of
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for an assay for digoxin. One antibody, however, AB 3,
has a much lower constant (107 M"1) and is probably not
valuable for a digoxin assay.
Cross Reactivity Studies:
Often, it is difficult to find an antibody which will
react only with the one substance against which it was
developed. This is the case with digoxin. This drug
is now known to be metabolized in some patients. Most
of these metabolites are very close in structure to
digoxin. In an ideal assay for digoxin, only that drug
should react with the antibody. It is known that for
digoxin, the ideal antibody has not been discovered.
There is also some doubt as to whether one wishes to
measure only digoxin since many of its metabolites are
also cardioactive. Including them in a
'digoxin'
result might help a physician to better evaluate his
patient's condition.
Some antibodies directed against digoxin also cross
react with various steroids and lipids. It is desired
that the antibody does not react with these (although
it is known that some of these are, indeed,
cardioactive) .
33
Two antibodies were chosen for cross reactivity
testing. Those potential cross reactants and digoxin,
itself, whose formula weights were known, were








made in pyridine using the stock solution made
initially- From those, a 1:100 dilution was made of
each in 0.25% BSA in PBS. These dilutions, from
10"5
M
to 10 M, including a
'0'
tube with 1% pyridine, were
added to the microtubes for testing.
Those potential cross reactants for which the formula
weight was not known were dissolved in pyridine at a
concentration of 1 mg/ml. Serial 1:10 dilutions of
each in pyridine followed. Finally, 1:100 dilutions of
each of those dilutions were made in 0.25% BSA in PBS.
Digoxin was also treated in this manner.
The experimental set up for cross reactivity was
basically the same as for Scatchard analysis.
Optimal
concentrations of labeled digoxin and antibody were
used. Fifty microliter samples of
each dilution of
competing substance
were added to the tube in the place
of unlabeled digoxin. Incubation and separation
proceeded as already described.
34
The counts obtained at the '0' concentration were
considered
'Bo,'
the counts from labeled digoxin bound
by the antibody when there was no competing substance
present.
'B'
was the count from the bound fraction
when a quantity of competing substance was present.
*B/Bo'
was calculated and multiplied by 100 to convert
to a percentage. %B/Bo was plotted against the log of
the concentration of the competing chemical. A curve
was fitted to the points. The log concentration at 50%
B/Bo was noted for each substance, including digoxin.
This value was converted to the actual concentration by
taking the antilog function. A ratio of those
concentrations and that for digoxin was made. That
number was multiplied by 100 to obtain 'percent cross
reactivity.'
This method is called the '50%
displacement'
method. From these numbers one can
estimate cross reactivity with some degree of
certainty.
Results :
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None of the lipids and steroids cross reacted with the
antibodies at the concentrations tested. However,
significant cross reactivity was found with many of the
digoxin metabolites. These metabolites and some other
cardiac drugs with similar structures are shown in
Figures 7 and 8 . Arrows point to where they differ in
structure from digoxin. It is not surprising to note
that digoxigenin, as well as the mono and bis
digitoxosides, cross react rather well with these
antibodies. The digoxin was linked to human serum
albumin through the sugar portion of the molecule to
cause an immune response in the rats. Therefore, the
antibody does not recognize the uniqueness of that area
of the molecule. Digitoxin differs from digoxin by not
having a hydroxyl group on carbon 12. Because of the
high extent of cross reactivity, it is likely that the
antibody does not recognize that portion of the
molecule particularly well. However, there is very
little cross reactivity shown when the analyte is
dihydrodigoxin. The molecule differs from digoxin only
in having the lactone ring in a reduced state.
Obviously, the antibody recognizes this area to a great
degree. Ouabain differs from digoxin at several sites
and it is, therefore, not a surprise that there is only














This figure and the one following on the next
page show the structure of digoxin and some
potential cross-reactants . Some are metabo
lites of digoxin. Others, such as digitoxin












cross reactivity of the digitoxigenin is unexplained.




This research project was successful. The objective
was to grow and characterize five monoclonal antibodies
against digoxin. The antibodies were collected and the
affinity constant and cross reactivity patterns
discovered.
It is obvious that the anti-digoxin antibodies will
cross react with many substances. Sometime in the
future, it might become evident to clinicians that they
need an idea of the total of cardioactive substances in
the patient's body. This is a concept that Soldin and
his coworkers are investigating
today.16
If the day
comes that cardioactivity and not 'digoxin
level'
is
requested, monoclonal antibodies will not be used, but
until then, all but one of the antibodies studied can
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